Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Warfarin biological effect in pancreatic cancer
NCT03536208Phase 1Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- May 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of warfarin in pancreatic adenocarcinoma (PDAC), sponsored by UT Southwestern Medical Center. Primary endpoint: Determine change in AXL pathway at 30 days. Planned start May 2019; status: withdrawn.
02
Drugs
warfarin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03536208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03536208.